title: Monoamine oxidase inhibitors revisited: what you should know.
authors.affiliation: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA. joseph.goldberg@mssm.edu
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Goldberg
authors.forename: Michael E
authors.initials: ME
authors.lastname: Thase
mesh_terms: D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D007520:Isocarboxazid / Q000008:administration & dosage / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010624:Phenelzine / Q000008:administration & dosage / Q000627:therapeutic use; D012642:Selegiline / Q000008:administration & dosage / Q000627:therapeutic use; D014191:Tranylcypromine / Q000008:administration & dosage / Q000627:therapeutic use; D014439:Tyramine / Q000502:physiology
chemical_list: D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D007520:Isocarboxazid; D014191:Tranylcypromine; D010624:Phenelzine; D014439:Tyramine